Four-in-one AIDS drug gets a OK in clinical trial

<p>An initial once-daily tablet that combines 4 drugs to quarrel HIV is as protected and effective as commonly-prescribed treatments opposite a AIDS virus, researchers reported in The Lancet Friday.</p>
<p>Doctors tested a new drug, called Quad, for a third and final proviso in that new curative products are vetted for reserve and effectiveness.</p>
<p>Publication in a British biography follows a recommendation in May by a <span>US Food and Drug Administration</span> (FDA) advisory row to approve Quad for formerly untreated adults putrescent with HIV-1. A final preference is approaching by August.</p>
<p>The initial hearing entailed contrast Quad opposite a three-in-one pill, <span>Atripla</span>, that given 2006 has been a customary diagnosis for a <span>human immunodeficiency virus</span> (HIV).</p>
<p>Researchers enrolled 700 patients in centres in <span>North America</span> and res...